12.09.2026 – Press Release: Sanofi completes the acquisition of Dynavax
1.26.2026 – 2026/27 Flu Prebook is Now Open
1.22.2026 – Resource: Childhood Vaccines: Five things parents should know
As long-held pediatric vaccination protocols become a topic of national discourse, a Stanford Medicine infectious disease specialist shares his insights. With the changing landscape surrounding vaccines, learning from all perspectives can help us all identify, understand and address concerns surrounding vaccines.
“Pediatric clinicians have a key role to play in shedding light on the issue. It starts with listening carefully to parents’ questions and input, according to Seth Hoffman, MD, an infectious disease specialist at Stanford Medicine and a member of the Stanford Maternal and Child Health Research Institute.”
1.20.2026 – GSK’s Shingrix Now Available in Pre-Filled Syringe
Starting 2/1/26 GSK’s Shingrix is now available to all Access Vaccines GSK members in PFS.
ACIP and CDC recommend vaccination of the following people to prevent shingles and post-herpetic neuralgia, the chronic pain that may linger long after the acute shingles rash resolves:
– All adults age 50 years and older who have not received Shingrix
– Adults age 19 years and older with a weakened immune system because of disease or treatments
Access Vaccines Members save up to: 9% off list (20$+ off per dose).
1.6.2026 – Fact Checked: U.S. Vaccine Recommendations are Appropriate for Children in the United States
There is robust evidence to support the safety, effectiveness and necessity of U.S. vaccine recommendations. Some public figures have falsely implied that the number of recommended vaccines for children in the United States could be linked to chronic health conditions or autism and have called for re-testing proven immunizations. Others have claimed that the U.S. childhood vaccine schedule is unsafe or unnecessary because the United States recommends more routine vaccines than some countries, like Denmark. The truth is that while vaccine guidance is largely similar across developed countries, it may differ by country due to different disease threats, population demographics, health systems, costs, government structures, vaccine availability, and programs for vaccine delivery.
12.10.2025 – New Study Suggests Shingles Vaccine Could Slow Dementia
For those living with dementia, new study suggests shingles vaccine could slow the disease. A new analysis of a vaccination program in Wales found that the shingles vaccine not only appeared to lower new dementia diagnoses by 20%, it also helped those who already have the disease.
Access Vaccines members save over 6% off list price on Shingrix when enrolled in the Access Vaccines GSK Arexvy Tier Discount Program – which provides increased discounts on Shingrix.
10.1.2025 – Access Vaccines Members Receive Increased Discounts on all Brands of COVID
The COVID season is fast approaching and with the recent ACIP vote allowing all patients who are at-risk or who’s doctor recommends them to to receive COVID immunizations – be prepared to protect your patients against this new strain.
All Access Vaccines members are eligible to receive discounts on their preferred brand of COVID.
Pfizer mRNA: 8-22% off
Moderna mRNA: 31-35% off
Sanofi Traditional Protein Based: 29% off
7.4.2025 – In-Season Flu Doses Available at Discounted Pricing for Access Vaccines Members
Flu season is upon us and ramping up, Access Vaccines offers all our members discounts on all brands of Flu vaccines. Protect your patients against the flu with updated flu vaccines for the 2025-26 season. Prior to ordering your in-season doses, make sure you are enrolled in the correct Access Vaccines Flu Discount Programs to receive discounted member pricing on your in-season orders.
– Seqirus: doses available and ready to ship
– Sanofi: doses available and ready to ship
– GSK: waitlist
– FluMist: doses available and ready to ship
7.4.2025 – Access Vaccines Provides Member Discounts on all Brands of Infant RSV Vaccines
With Merck’s new infant rsv vaccines, Access Vaccines member have choice with which brand they choose to administer to their infant patients. Regardless of brand, AV members save on all purchases on infant rsv vaccines. Protect your infant patients born during RSV season with these groundbreaking new vaccines.
– Merck Enflonsia: 21% member discount
– Sanofi Beyfortus: 16% member discount t
6.25.25 – New Discount Program Available for Pfizer: Pfizer Portfolio Program
Pfizer Portfolio Program: for accounts utilizing Pfizer’s portfolio of vaccines, earn an additional 2% off all brands through this new tier of discount with Pfizer.
2% Additional Discount*:
– Prevnar: 16.5% total discount
– Trumenba: 29% total discount
– COVID: 12+yrs: 26% total discount & 6mo-12yr: 12% total discount
– Abrysvo: 14% total discount
*2% Additional Discount: applied in addition to to already discounts Select Pfizer Member pricing, extra 2% applied in addition to 2% Prompt Pay.
Eligible Members: must purchase more than 80% market share for all Pfizer products (if administered).
Start Date: July 1, 2025
4.15.25 – Access Vaccines Members Receive Lowest National Pricing on all Brands of Pneumococcal Vaccines
Merck Discount Program
– Vaxneuvance: 21% discount *includes Vaccineshoppe online discount, prompt pay
– Capvaxive: 21% discount *includes Vaccineshoppe online discount, prompt pay
Pfizer Discount Program
– Prevnar 20: 14.5% discount
3.25.25- Discounts for Members Available on all Brands of Rotavirus Vaccine
Access Vaccines members receive discounted member pricing on Rotavirus Vaccines. Protect your infant patients from Rotavirus at discounted member pricing. Both brands available at discounted member pricing:
– Merck: Rotateq: Members save 14%
– GSK: Rotarix: Members save 23%
2.5.25 – 2025/26 Flu Prebook is Now Open
The prebook period for Access Vaccines members for the 2025/26 flu season has officially started. Now is the time to reserve your doses. Access Vaccines members have the choice between all brands of flu, at the lowest national prices for each brand:
Seqirus:
Flucelvax (6+ months) *cell-based
– Afluria (6+ months)
– FluAd (65+ years)
Sanofi:
– Fluzone (6+ months)
– Flublok (18+ years)
– Fluzone High Dose (65+ years)
GSK:
– FluLaval (6+ months)
– Fluarix (6+months)
AstraZeneca:
– FluMist (2-49 years)
1.27.25 – CDC Update: ACIP Recommended Adult Immunizations: Highlighting Pneumococcal
The ACIP has published its updated recommendations for Adult Immunizations. Including in its recommendations, the newest adult pneumococcal vaccine covering 21 conjugates: Capvaxive. The ACIP recommends to vaccinate against pneumococcal with one of the following vaccines:
- PCV 15 (Vaxneuvance)
- Prevnar 20
- Capvaxive
Access Vaccines strives to provide members the lowest prices on vaccines recommended by ACIP and supported by the CDC. Access Vaccines members receive discounted pricing on all brands of pneumococcal vaccines. Become an Access Vaccines member today and save on all your pneumococcal purchases.
11.15.24 – CAPVAXIVE Recieves Significant CDC Recommendation
Merck’s pneumococcal conjugate vaccine Capvaxive recently scored a key recommendation from the Centers for Disease Control and Prevention’s (CDC’s) vaccine advisory group to expand its use to all adults aged 50 and older, compared to a previous endorsement for people 65 and older. About 120 million people in the U.S. are over the age of 50, with 60 million between the ages of 50 to 64.
CAPVAXIVE is the only pneumococcal vaccine specifically designed to protect adults 50 and older with 21 serotypes. The 50 and older age range account for 84% of the disease found in that population, according to Merck.
10.30.24 – CDC Updates Recommendations for COVID-19 and Pneumococcal Vaccinations
CDC Recommends Second Dose of 2024-2025 COVID-19 Vaccine for 2 Groups:
– 65 Years and Older and for People Who are Moderately or Severely Immunocompromised
– Everyone 6 months and older who are moderately or severely immunocompromised
CDC also lowered the age for which it recommends adult pneumococcal vaccination from 65 to 50 years old. Pneumococcal bacteria can cause serious illnesses, including pneumonia, meningitis, and bloodstream infections.
10.25.24 – FDA Approves First Ever RSV Vaccine Indicated for Adults Younger than 50: Abrysvo by Pfizer
The FDA has endorsed Pfizer’s respiratory syncytial virus (RSV) vaccine Abrysvo for adults ages 18 to 59 who are at an increased risk of developing lower respiratory tract disease (LRTD). The approval makes the shot the first of its kind for adults who are younger than 50 years old. Among U.S. adults ages 18 to 49, 9.5% have an underlying chronic condition that increases their risk of developing severe disease, Pfizer said. In the 50 to 64 age group, the prevalence of at-risk individuals rises to 24%.
Abrysvo is a vaccine indicated for:
– the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in people 60 years of age and older
– the prevention of LRTD caused by RSV in people 18 through 59 years of age who are at increased risk for LRTD caused by RSV
– pregnant individuals at 32 through 36 weeks gestational age for the prevention of LRTD and severe LRTD caused by RSV in infants from birth through 6 months of age.
10.8.24 – The CDC recommends an RSV vaccine for all adults ages 75 years and older and for adults ages 60–74 years who are at increased risk of severe RSV.
Three RSV vaccines are licensed by the U.S. Food and Drug Administration for use in adults ages 60 and older in the United States:
– GSK’s Arexvy
– Moderna’s mResvia
– Pfizer’s Abrysvo
If your patient has already gotten an RSV vaccine, you do not need to get another one at this time. Your patients can get one at any time, but the best time to get vaccinated is in late summer into fall.
9.18.24 – GSK Reports Positive Data From Co-administration Of RSV And Shingles Vaccines
GSK announces administration of its respiratory syncytial virus (RSV) vaccine: Arexvy and Shingles shot: Shingrix – together generated the same immune response in a late-stage trial as separate adminstration of the vaccines.
The trial testing the immune response of co-administration of GSK’s blockbuster vaccines, Shingrix and Arexvy, in adults over 50 years of age, met the main goal of the study.
RSV causes over 177,000 hospitalizations and 14,000 deaths in the United States annually, while over 1 million people develop shingles every year in the country.
7.31.24 – Groundbreaking: Bavarian Nordic begins commercial launch of mpox vaccine Jynneos in US
After years relying on the U.S. government to stockpile and distribute Jynneos, Bavarian Nordic is launching the mpox vaccine into the commercial market.
Jynneos, the only FDA-approved mpox vaccine, is now commercially available in the U.S., Bavarian Nordic announced Tuesday. The commercial rollout means that interested individuals can access the shot at local pharmacies and physician offices, in addition to the limited number of clinics designated by health authorities.
The launch builds on Jynneos’ availability through public health channels since an mpox—then known as monkeypox—outbreak in 2022. It also follows a unanimous decision in October from the U.S. CDC’s Advisory Committee on Immunization Practices to recommend Jynneos as a routine vaccination in adults at risk of mpox infection, backing the shot’s use beyond an outbreak.
7.15.24 – CDC Recommends Vaxelis in American Indian and Alaska Native Populations
Invasive Haemophilus influenzae type b (Hib) disease is a rare but serious bacterial infection that disproportionally affects American Indian and Alaska Native infants. Until now, PedvaxHIB was the only Hib vaccine preferentially recommended over other Hib vaccine options for these infants because it provides a protective antibody response after the first dose.
ACIP voted to recommend that Vaxelis be included in the preferential recommendation for American Indian and Alaska Native infants based on the Hib component. New immunogenicity data after the first dose of Vaxelis are available now and supported the recommendation.
4.29.24 – Access Vaccines Merck Discount Program Provides Lowest National Price on Gardasil
Access Vaccines Merck Discount Program Provides Lowest National Price on Gardasil
The Access Vaccines Merck Discount Program provides members with the lowest national price on Gardasil. GARDASIL 9 is a vaccine for patients 9 through 45 years of age for the prevention of certain cancers and other diseases caused by 9 types of human papillomavirus (HPV).
According to a CDC model in 2012-2016: In men, oropharyngeal cancer has been the most prevalent HPV-attributable cancer in the US. Certain HPV-related oropharyngeal cancers affect men (~10,500) ~5x more than women (~2,100).
The oropharyngeal and head and neck cancer indication is approved under accelerated approval based on effectiveness in preventing HPV-related anogenital disease. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Access Vaccines is proud to offer our members the lowest national price on Gardasil. Become a member today and save.
4.15.24 – Access Vaccines Now Offers Discount on GSK and Moderna Vaccines to Independent Pharmacies
Access Vaccines is proud to announce we are now able to provide discounted member pricing to Independent Pharmacies. For the first time in the history of PBG’s, Access Vaccines is now able to offer our services to Independent Pharmacies throughout the nation.
– Member discounts on GSK vaccines including Shingrix and Flu.
– Member discounts on all Moderna vaccines.
Independent Pharmacies can now take advantage of discount member pricing through Access Vaccines. Enroll your location or group in the Access Vaccines Pharmacy Discount Program today to save on your GSK and Moderna vaccine purchases.
4.10.24 – 2024-25 Influenza Vaccines Transitioning to Trivalent Formulation
U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) provided recommendations for the TIV viral strain selection of influenza vaccines, which align with the February 2024 World Health Organization (WHO) annual recommendations.
3.7.24 – Access Vaccines is Proud to Announce our Newest Partnership: Merck Vaccines
Proud to announce our newest partnership with Merck Vaccines. This partnership continues to expand our portfolio, bringing more options and savings to our members on all administered brands.
The Acces Vaccines Merck Discount Program offers qualifying members discounts on Merck Vaccines. The program provides the Lowest National Price on Gardasil, Rotateq and Vaxneuvance (PCV15). Access Vaccines members who join the Merck Discount program will receive discounts on all Merck Vaccines.
Contact Access Vaccines to join the Merck Discount Program and start saving on all your Merck Vaccine purchases today. Merck Discount Program.
10.19.23 – CDC Recommends Pfizer or Sanofi RSV Vaccine to Provide Protection Against Infant RSV
ACIP and CDC recommended RSVpreF vaccine using seasonal administration (i.e., during September through end of January in most of the continental United States) for pregnant persons as a one-time dose at 32–36 weeks’ gestation for prevention of RSV-associated LRTI in infants aged <6 months. Either maternal RSVpreF vaccination during pregnancy or nirsevimab administration to the infant is recommended to prevent RSV-associated LRTI among infants, but both are not needed for most infants. All infants should be protected against RSV-associated LRTI through use of one of these products.
8.31.23 – GSK’s RSV Arexvy: RSV Vaccines Remains Effective Against Distinct Viral Variants
GSK’s Arexvy vaccine for respiratory syncytial virus (RSV) — the first to be approved for older adults — can remain effective against a range of variants and produces strong antibody responses against distinct viral strains, according to a new study. The study results, published in the journal Science Translational Medicine, indicate that the vaccine could offer enduring protection against both contemporary RSV and future variants, especially when combined with vaccine adjuvants.
Sanofi today announced that it has completed theacquisition of Dynavax Technologies Corporation (Dynavax). The acquisition includes Dynavax’s adult hepatitis B vaccine HEPLISAV-B, which is currently marketed in the US and is differentiated by its two-dose regimen over one month. It also includes Dynavax’s shingles vaccine candidate (Z-1018), which is currently in phase 1/2 studies, and additional vaccine pipeline projects.
What this means for Access Vaccines Members? All members enrolled for discounts will receive discounted member pricing on Dynavax vaccines.